Long-term Prognosis and Valve Durability of TAVR
Long-term Prognosis and Valve Durability of Transcatheter Aortic Valve Replacement for Aortic Valve Disease: a Real-world, Prospective, Single-center, Observational Study
Xijing Hospital
1,000 participants
Jan 1, 2016
OBSERVATIONAL
Conditions
Summary
This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner.
Eligibility
Inclusion Criteria4
- Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.
- \. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form
- \. Patients with aortic stenosis or aortic valve insufficiency who were evaluated by the Heart team and underwent TAVR therapy
- \. Patients who understand the purpose of the study, agree to participate in the trial and sign the informed consent form
Exclusion Criteria2
- \. Patients who cannot provide informed consent
- \. Patients who are participating in other clinical trials
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A total of 1000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled. Clinical follow-up will be conducted in the periprocedural and after TAVR at 1 month, 5 years, and 10 years
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06379386